COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 2 for:    MG1111
Previous Study | Return to List | Next Study

Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02367638
Recruitment Status : Completed
First Posted : February 20, 2015
Last Update Posted : April 27, 2017
Information provided by (Responsible Party):
Green Cross Corporation

Brief Summary:
The purpose of this study is to determine whether varicella live vaccine is safe and effective in the healthy adults.

Condition or disease Intervention/treatment Phase
Varicella (Chicken Pox) Biological: MG1111 Biological: VARIVAX Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: A Single-center, Dose Block-randomized, Single-blind, Active-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of MG1111 in Healthy Adults
Study Start Date : March 2015
Actual Primary Completion Date : July 2015

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Shingles
MedlinePlus related topics: Chickenpox

Arm Intervention/treatment
Experimental: MG1111 Biological: MG1111
Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection

Active Comparator: VARIVAX Biological: VARIVAX
VARIVAX is administered by subcutaneous injection

Primary Outcome Measures :
  1. To evaluate the solicited adverse events and unsolicited adverse events during 7 days after vaccination [ Time Frame: 7 days ]
  2. To evaluate the unsolicited adverse events during 42 days after vaccination [ Time Frame: 42 days ]

Secondary Outcome Measures :
  1. To evaluate the efficacy of Geometric mean titer (GMT) and GMT ratio using FAMA assay antibody titer at Day 42 [ Time Frame: 42 days ]
  2. To evaluate the efficacy of Geometric mean titer (GMT) and GMT ratio using gpELISA antibody titer at Day 42 [ Time Frame: 42 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy male and female individuals between 20 and 55 years of age at screening test

    • In the case of female, individuals must be applicable for one of the following;
    • In the case of female of childbearing potential, any negative pregnancy test using urine hCG at screening
    • Menopausal for at least 2 years
    • Surgical sterilization (status after hysterectomy, bilateral oophorectomy, bilateral tubal ligation or the status using other contraceptive methods)
    • Monogamous relationship with vasectomized partner prior to screening visit
    • Individuals who are used acceptable contraceptive methods from 3 month prior to the subject's study entry to 1 month after vaccination (acceptable contraceptive methods; condom, diaphragm or cervical cap)
  2. If male who is sexually active with the female "of childbearing potential" , the individuals who agree to use any of the acceptable contraceptive methods during this study period and agree to not donate the sperm until 1 month
  3. At screening visits, individuals who are over 55 kg in man, over 50kg in woman and whose ideal body weight is within 20 % ((ideal body weight = (height -100)*0.9)
  4. Individual who has no clinically significant abnormalities in screening test within 28 days prior to vaccination
  5. Individuals who were voluntarily signed informed consent form after receiving education about this study and able to comply with the requirements for the study

Exclusion Criteria:

  1. Individuals who received any other vaccines within 4 weeks prior to the screening visit
  2. Individuals who are planning to receive the other vaccines during this study
  3. Individuals who had wound, scar, tattoo, dermatological disorders or injection affecting safety evaluation
  4. Individuals with alcohol or caffeine abuse or heavy smoker (caffeine : >5 cups/day, alcohol : 210g/week, smoke : 10 /day)
  5. Individuals who received any other investigational product within 90 days prior to vaccination
  6. individuals who donated the whole blood within 60 days or apheresis within 30 days prior to vaccinating investigational product
  7. Individuals who administered with another prescription medicine, herbal medicine within 14 days or over-the-counter drug or vitamins within 7 days before vaccination
  8. Individuals with history or illness affecting immune system (1) individuals with continuously anti-viral therapy within 6 months prior to participating in this study (2) Individuals with leukemia, lymphoma, other malignant neoplasm or hematodyscrasia affecting the bone marrow or lymphatic system (3) Immunodeficient individuals (primary or acquired immunodeficiency states, immunodeficiency, hypogammaglobulinemia, dysgammaglobulinemia) (4) Individuals who are receiving immunosuppressive therapy (5) Individuals who have treated immunoglobulin or blood-derived products within 6 months of enrollment (6) Individuals with a family history of congenital or hereditary immunodeficiency
  9. Individuals with any clinically relevant history of other disease or disorder - gastrointestinal, respiratory, renal, hepatic, neurological (Guillain-Barre syndrome), psychiatric or malignant tumor
  10. Individuals with any febrile illness or body temperature ≥38℃ before vaccination
  11. Individuals known hypersensitivity or allergy to components of investigational product (including gelatin and neomycin)
  12. Individuals who are any clinically significant abnormality following the investigator's review of the pre-study physical examination, ECG, and clinical laboratory tests
  13. Pregnancy or breastfeeding
  14. Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study
Layout table for additonal information
Responsible Party: Green Cross Corporation Identifier: NCT02367638    
Other Study ID Numbers: MG1111_P1
First Posted: February 20, 2015    Key Record Dates
Last Update Posted: April 27, 2017
Last Verified: April 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Varicella Zoster Virus Infection
Herpesviridae Infections
DNA Virus Infections
Virus Diseases